LL-37 peptide: what your gut already makes, and what the trials actually found

LL-37 has an unusual place in the peptide conversation. Most of what gets sold online as a “research peptide” is a fragment or analog someone designed. LL-37 is different: it is a molecule your own body makes, including in the lining of your colon, as part of its everyday defense against microbes. That real biology is exactly what makes the hype so easy to write. If your body uses it to fight bacteria and repair tissue, the pitch goes, more of it must be better. This page looks at that claim from the gut and immune side: what LL-37 does where it naturally lives, what the handful of human trials actually reported, what side effects have shown up, and what the online conversation gets right and wrong. For the full substance overview, see the hub’s LL-37 (cathelicidin) explainer.

What is the LL-37 peptide?

LL-37 is the active form of human cathelicidin, a 37-amino-acid antimicrobial peptide, and it is the only member of the cathelicidin family that humans make. A 2016 review in Inflammatory Bowel Diseases describes it as “the only member of the cathelicidin family of host defense peptides expressed in humans,” produced mainly by white blood cells and epithelial cells, with roles in fighting pathogens, inflammation and tissue repair (Sun et al., 2016; PMID 27135484). The name comes from its first two amino acids (two leucines, “LL”) and its length (37), which you can see at the end of the cathelicidin precursor’s sequence (UniProt P49913). When people search “LL37,” “LL-37 peptide” or “cathelicidin LL-37,” they are all talking about the same molecule.

One detail matters for anyone reading supplement-style claims: the body ties LL-37 production to vitamin D. A 2005 study in the FASEB Journal showed that the active form of vitamin D switches on the human cathelicidin gene through a vitamin D response element in its promoter, including in colon cancer cell lines and bone-marrow-derived immune cells (Gombart et al., 2005; PMID 15985530). That is laboratory evidence about how the body regulates its own LL-37, not evidence that taking vitamin D, or LL-37 itself, produces a health benefit.

What does LL-37 do in the gut?

In the gut, LL-37 is part of the lining’s built-in chemical defense, and its job looks protective in some experiments and disruptive in others. A 2003 study in the journal Gut found LL-37 in the healthy human colon and ileum, “restricted to differentiated epithelial cells,” and showed in cell experiments that butyrate and other short-chain fatty acids (the compounds gut bacteria make from fiber) increased its expression (Schauber et al., 2003, Gut; PMC1773650). The authors suggested this “may provide a rationale for dietary modulation of mucosal defence mechanisms,” a hypothesis, not a tested treatment.

The strongest protective signal comes from mice. A 2011 study in Gastroenterology found that mice genetically unable to make cathelicidin developed a more severe form of chemically induced (DSS) colitis, and concluded that “Cathelicidin protects against colitis induction in mice” (Koon et al., 2011, Gastroenterology; PMC3199285). The 2016 IBD review adds a human wrinkle: LL-37 has been reported as overexpressed in the colon of people with ulcerative colitis but unchanged in Crohn’s disease, which the authors call evidence of “the intricate functions of LL-37 in IBD” (Sun et al., 2016).

And then there is the result the marketing never mentions. A 2025 cell study found that adding LL-37 directly to a line of human colon epithelial cells (T84) caused “a rapid and transient increase in epithelial cell permeability” by breaking down two tight-junction proteins, occludin and claudin-2; the authors note this temporary disruption “may lead to a ‘leaky gut’” (Kilari et al., 2025; PMID 39837472). That is a cell-dish finding, but it is a useful corrective to the idea that more LL-37 automatically means a healthier gut lining.

What are the claimed LL-37 peptide benefits, and which have evidence?

The benefits claimed online fall into three buckets: fighting infections, calming gut and immune inflammation, and healing wounds. Only the third has been tested in controlled human trials, and only as a topical treatment on chronic ulcers. The table below lays out each claim against the level of evidence behind it.

What have LL-37 clinical trials found?

LL-37 clinical trials have been few and small, and every one of them tested it as a medicine applied to or injected into a specific lesion, not as a general gut or immune treatment. The first was a 34-person, first-in-human trial in hard-to-heal venous leg ulcers, published in Wound Repair and Regeneration in 2014. LL-37 (at 0.5, 1.6 or 3.2 mg/mL) or placebo was applied to the ulcer twice weekly for four weeks; the two lower concentrations tested showed healing-rate constants “approximately six- and threefold higher than for placebo,” while the highest concentration showed “No difference in healing” versus placebo, and there were “no safety concerns regarding local or systemic adverse events” (Grönberg et al., 2014; PMID 25041740). PeptideAgent’s LL-37 profile likewise lists the leg-ulcer gel trials as the only human trials and notes that there is no human data for injections.

A second, independent trial in Indonesia randomized 25 people with uninfected or mildly infected diabetic foot ulcers to an LL-37 cream or a placebo cream, twice a week for four weeks. The LL-37 group showed a consistently greater increase in granulation (new healing tissue), but the differences in wound-area shrinkage between the groups were not statistically significant, and the cream “did not decrease the levels of IL-1α and TNF-α and the number of aerobic bacteria colonization” compared with placebo (Miranda et al., 2023, Archives of Dermatological Research; PMC10514151). In other words, it improved one healing marker in a very small trial, but it did not measurably beat placebo on the antibacterial and anti-inflammatory effects people most often cite as LL-37 benefits.

The third line of human testing was in cancer. MD Anderson Cancer Center registered a phase 1/2 study of LL-37 injected directly into melanoma lesions; the registry lists it as completed with 4 participants enrolled (ClinicalTrials.gov, NCT02225366). That is an early safety and feasibility study, not evidence of benefit.

What did Promore Pharma’s HEAL LL-37 trial show?

Promore Pharma’s HEAL LL-37 trial, the largest LL-37 study so far, did not meet its main goal. It was a phase IIb, double-blind, placebo-controlled study in 148 patients with hard-to-heal venous leg ulcers, comparing two concentrations of topical LL-37 (the company’s name for it is ropocamptide) with placebo, on top of standard compression therapy. The published results in Wound Repair and Regeneration state that analysis of the full study population “did not identify any significant improvement in healing in patients treated with LL-37 as compared with the placebo” (Mahlapuu et al., 2021; PMC9298190).

The positive headline you may see attached to this trial comes from a subgroup. A post hoc analysis of patients whose wounds were at least 10 cm² found statistically significant improvement in several related healing measures, and the drug “was well tolerated and safe in both dose strengths.” The authors themselves describe that subgroup result as “an interesting observation” that warrants “a further study adequately powered” to test it (Mahlapuu et al., 2021). In a November 20, 2020 press release, Promore acknowledged the subgroup analysis “was not part of the original statistical analysis plan,” while calling the large-wound findings “clear and convincing” and reporting complete healing in 28.8% of large wounds on the 0.5 mg/ml concentration versus 8.1% on placebo (Promore Pharma press release, 2020); the published paper puts the same figure at 28.1% versus 8.1%, with 21 large-wound patients on 0.5 mg/mL and 24 on placebo (Mahlapuu et al., 2021). However confidently a company frames it, a post hoc subgroup is a reason to run another trial, not a result to build claims on, which is how the published paper frames it.

Two other things are worth noticing. Promore says 0.5 mg/ml, the lowest concentration tested, looked most effective in both of its trials (Promore Pharma press release, 2020), and the 2014 trial’s highest concentration did no better than placebo, so “more” did not mean “better” even on a wound. And none of these trials tested LL-37 injected under the skin for general wellness, which is how it is usually discussed online.

What are LL-37’s side effects?

In the topical wound trials, LL-37 was reported as well tolerated, with no safety concerns flagged by the investigators (Grönberg et al., 2014; Mahlapuu et al., 2021). Injected use is a different picture. A 2018 case report describes a 63-year-old patient with advanced melanoma who received LL-37 injected into her tumors, the approach tested in the phase 1 melanoma trial; after eight weekly injections she developed multiple wart-like and blistering skin lesions on her trunk and limbs; biopsies showed inflammation with atypical skin-cell growth, and all lesions resolved within two months of stopping the injections (Dolkar et al., 2018, Journal of Cutaneous Pathology; PMID 29665030). That is one patient, in a cancer setting, but it is the clearest published description of what injected LL-37 did in a person.

There is also a biological reason for caution in people with autoimmune skin disease. A 2014 study in Nature Communications found that two-thirds of patients with moderate-to-severe plaque psoriasis carried T cells specific for LL-37, and that their presence “correlates significantly with disease activity” (Lande et al., 2014; PMID 25470744). Put together with the 2025 tight-junction finding in colon cells, the honest summary is that LL-37 can push inflammation in either direction depending on the setting. No study has established a safe dose, duration or route for self-administered LL-37, and products sold online as “research use only” carry no guarantee of purity, content or sterility.

How does LL-37 compare with KPV and thymosin alpha-1?

LL-37 often gets grouped with KPV and thymosin alpha-1 as “immune peptides,” but the three sit at very different evidence levels. Thymosin alpha-1 is the only one of the three that is a licensed medicine anywhere: its synthetic form, thymalfasin, “is approved in more than 35 countries for the treatment of hepatitis B and C,” though not by the FDA (Dominari et al., 2020; PMC7747025). KPV, the α-MSH(11-13) tripeptide, has been studied in mouse colitis models, and a 2023 review of the field notes that “Much of the available evidence is, in fact, preclinical” (Gravina et al., 2023; PMC10378568).

For the details behind the other two rows, see our pages on KPV and inflammation research and thymosin alpha-1 and immune modulation. No study has tested LL-37 stacked or blended with either one, so any “immune stack” that includes it is untested as a combination. Our guide to peptides for gut health compares all of these on the gut evidence specifically.

What does LL-37 cost?

We do not report a price for LL-37 here. Bodybuilding Peptides, the store this network is affiliated with, does not sell it, so there is no catalog price we can verify and date, and prices quoted on “research use only” sites say nothing about what is actually in the vial. The more useful cost question is the one the trials raise: the only versions tested in people were made for clinical trials and applied to wounds, which is not what an online purchase gets you.

What are people saying about LL-37?

Online, LL-37 is name-checked far more often than it is discussed in depth. Our community tracker, summarized on the hub’s LL-37 explainer, collected 13 public posts on X from July 10 to 14, 2026; the themes below are anecdotes, not evidence.

• “The body’s own antibiotic.” Several posts describe LL-37 as an immune peptide that punches holes in bacterial membranes and signals wound repair. That description matches the basic biology above; what the posts skip is that the human trials tested it on wounds, not on infections.
• MRSA enthusiasm. One commenter calls LL-37 underrated and says it helps with MRSA infections. No such result appears in the threads as a personal outcome, and no published human trial has tested LL-37 against MRSA.
• The vitamin D connection. Some posts point out that vitamin D drives cathelicidin production. That is accurate as laboratory biology (Gombart et al., 2005), and it is the one theme where the community is closest to the science.
• Listed, not discussed. Much of the content places LL-37 in peptide cheat sheets and catalogs among many other compounds, with few detailed first-hand reports.

The summary rated the sample as leaning positive with a sizable skeptical share, an informal impression from a small set of posts rather than a measurement.

Why the hype outruns the evidence

The gap comes from a reasonable-sounding leap. “Your body makes LL-37 to defend the gut and heal wounds” is true. “So taking extra LL-37 will strengthen your gut and immune system” has never been tested, and the evidence that does exist complicates it: the same peptide protected mice from colitis, loosened the junctions between human colon cells in a dish, and is a target of the immune attack in psoriasis. The human trials, meanwhile, were about ulcers, used topical preparations at concentrations where less looked better than more, and the biggest one missed its primary endpoint. If you are dealing with a chronic gut or immune problem, our overview of peptides and chronic conditions in 2026 puts LL-37 alongside the other peptides people ask about, and a licensed provider can weigh options that have human evidence behind them.

Status: Not FDA-approved. What these status terms mean.

Key takeaways

• LL-37 is the only human cathelicidin, an antimicrobial peptide made by gut lining and immune cells; vitamin D switches on its gene.
• In the gut, the evidence points both ways: protective in mouse colitis, but it disrupted tight junctions in human colon cells in a 2025 lab study.
• Human trials are small and topical: a 34-person leg ulcer trial and a 25-person diabetic foot ulcer trial reported some positive healing signals, but Promore Pharma’s 148-patient HEAL LL-37 trial found no significant benefit in its full population.
• Topical use was well tolerated in trials; injections into melanoma tumors were followed by skin lesions in one reported patient, which resolved after stopping.
• No human study has tested LL-37 for gut health, immune support or infections, and no safe self-administered dose has been established.